DRAK2 anticorps (C-Term)

N° du produit ABIN499770

Détail du produit anti-DRAK2 anticorps

Antigène: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp DRAK2 est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), Enzyme Immunoassay (EIA)

Specificité: DRAK2 antibody was raised against a peptide corresponding to amino acids 351 to 365 of human DRAK2. It has no cross responses to DAP or ZIP kinases.

Purification: Ion exchange chromatography

Immunogène: Human DRAK2 (C-Terminus) Peptide

Isotype: IgG

Information d'application

Indications d'application: ELISA. Western Blot: 1/500 to 1/1000. An approximately 45 kDa band can be detected. Theapproximately 70 kDa band is probably non-related to DRAK2 although it is peptideblockable. Immunocytochemistry.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Buffer: PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C.

Détails sur DRAK2

Antigène: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Autre désignation: STK17B / DRAK2 (STK17B Produits)

Synonymes: anticorps zgc:65989, anticorps STK17B, anticorps DRAK2, anticorps Drak2, anticorps 3110009A03Rik, anticorps AI120141, anticorps serine/threonine kinase 17b (apoptosis-inducing), anticorps serine/threonine kinase 17b, anticorps stk17b, anticorps STK17B, anticorps Stk17b

Sujet: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues (1).Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B

ID gène: 9262

UniProt: O94768